251 286 - Biotech Bayern

Multimetrix GmbH
BIOTECH DNA/PROTEIN ANALYTICS
Keywords: Clinical Diagnostics, Chip / Array Technology, Autoimmune Diseases,
Clinical Research
Multimetrix's major field of expertise is based on the Luminex technology. This
technology allows the simultaneous quantitative measurement of up to one
hundred different parameters in a single drop of a liquid sample. At the same
time it saves time and money even when compared to a single parameter
measurement using conventional methods. Due to its high flexibility the
Luminex technology can be used to measure all kinds of different analytes that
are characterized by specific binding of two defined molecular interaction
partners, e.g. antigens and antibodies, enzymes and substrates, receptors and
ligands and complementary nucleic acids. The Luminex technology is particularly
suitable for high-throughput applications in the fields of laboratory diagnostics,
pharmacological screening, expression profiling and SNP analysis.
The advantages of the Luminex technology as compared to conventional assay
systems such as ELISA and Western blotting are obvious: it is fully automated,
smaller sample volumes are needed and it provides higher sensitivity and
specificity at a lower price.
Multimetrix develops multiplex test systems for applications in the fields of
diagnostics, pharmacological screening and quality control.
Multimetrix offers the assay development on demand including all required
validation and quality assurance procedures as well as a testing service for
detection of multiple analytes on customer request.
multimmune GmbH, c/o Strahlentherapie
der TU München
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy,
Vaccines, Oncology
multimmune is a biopharmaceutical company dedicated to the discovery and
development of new products for the treatment of cancer. The company
focuses on the development of drug candidates to treat heat shock protein 70
(Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker
expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon,
pancreas.
Currently, four approaches are being explored to destroy cancer cells:
(1) by extracorporal activation of Natural Killer (NK) cells with a synthetic peptide
(ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical),
(3) by direct infusion of an Hsp70 peptide (R&D), (4) by
inducing tumor specific apoptosis with a serine protease(R&D).
Contact:
Dipl.-Biol. Elisabeth Dove
Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 30 74 386
Fax: +49 (0) 941 30 74 798
E-Mail: info@multimetrix.com
Internet: www.multimetrix.com
Contact:
Dr. Claus Botzler
Ismaninger Str. 22
D-81675 München
Phone: +49 (0) 89 4140-4298
Fax: +49 (0) 89 4140-4299
E-Mail: info@multimmune.de
Internet: www.multimmune.de
87